Publication | Closed Access

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

Breast OncologyMedicineChemotherapy De-escalationPathologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentOncology